Fairvalue-Calculator Fairvalue-Calculator
EN DE

Oryzon Genomics S.A (ORYZF) Fair Value & Analysis

Healthcare · US · Market cap $283M

Price$3.65
Fair Value$6.95
Upside+90.7%
Quality82/100
Evidence: Low Range $5.21 – $8.69

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Oryzon Genomics S.A (ORYZF) currently trades at $3.65, while our model-based Fair Value estimate is $6.95 — implying the stock looks roughly 90.7% undervalued today. We read business quality at 82/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital …

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Oryzon Genomics S.A (ORYZF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $6.95 versus a price of $3.65 — about +91% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ORYZF?
Our 21-model fair value for Oryzon Genomics S.A is $6.95 (as of Jun 24, 2026), built from audited fundamentals. The current price is $3.65.
What is the quality score of ORYZF?
Oryzon Genomics S.A has a Quality Score of 82/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.